Inhibition of IRAK4 by microbial trimethylamine blunts metabolic inflammation and ameliorates glycemic control
Julien Chilloux,Francois Brial,Amandine Everard,David Smyth,Petros Andrikopoulos,Liyong Zhang,Hubert Plovier,Antonis Myridakis,Lesley Hoyles,José Maria Moreno-Navarrete,Jèssica Latorre Luque,Viviana Casagrande,Rosella Menghini,Blerina Ahmetaj-Shala,Christine Blancher,Laura Martinez-Gili,Selin Gencer,Jane F. Fearnside,Richard H. Barton,Ana Luisa Neves,Alice R. Rothwell,Christelle Gérard,Sophie Calderari,Mark J. Williamson,Julian E. Fuchs,Lata Govada,Claire L. Boulangé,Saroor Patel,James Scott,Mark Thursz,Naomi Chayen,Robert C. Glen,Nigel J. Gooderham,Jeremy K. Nicholson,Massimo Federici,José-Manuel Fernández-Real,Dominique Gauguier,Peter P. Liu,Patrice D. Cani,Marc-Emmanuel Dumas
DOI: https://doi.org/10.1101/277434
2024-01-30
Abstract:The global type 2 diabetes epidemic is a major health crisis and there is a critical need for innovative strategies to fight it. Although the microbiome plays important roles in the onset of insulin resistance (IR) and low-grade inflammation, the microbial compounds regulating these phenomena remain to be discovered. Here, we reveal that the microbiome inhibits a central kinase, eliciting immune and metabolic benefits. Through a series of experiments based on choline supplementation, blocking trimethylamine (TMA) production then administering TMA, we demonstrate that TMA decouples inflammation and IR from obesity in the context of high-fat diet (HFD) feeding. Through kinome screens, we reveal TMA specifically inhibits Interleukin-1 Receptor-associated Kinase 4 (IRAK4), a central kinase integrating signals from various toll-like receptors and cytokine receptors. TMA blunts TLR4 signalling in primary human hepatocytes and peripheral blood monocytic cells, and improves mouse survival after a lipopolysaccharide-induced septic shock. Consistent with this, genetic deletion and chemical inhibition of IRAK4 result in similar metabolic and immune improvements in HFD. In summary, TMA appears to be a key microbial compound inhibiting IRAK4 and mediating metabolic and immune effects with benefits upon HFD. Thereby we highlight the critical contribution of the microbial signalling metabolome in homeostatic regulation of host disease and the emerging role of the kinome in microbial–mammalian chemical crosstalk.
Systems Biology